阿司匹林和氯吡格雷抵抗相关的遗传学机制研究

被引:23
作者
王宝祥
李焰生
机构
[1] 上海交通大学医学院附属仁济医院神经内科
关键词
阿司匹林; 血小板聚集抑制剂; 遗传学; 花生四烯酸; 多态性,单核苷酸; 基因型;
D O I
暂无
中图分类号
R743.3 [急性脑血管疾病(中风)]; R969.2 [药物相互作用];
学科分类号
1002 ; 100602 ; 100706 ;
摘要
<正>在急性缺血性脑卒中和短暂性脑缺血发作(TIA)患者中,以阿司匹林联合氯吡格雷为基础的抗血小板治疗,优于单独使用阿司匹林,并且能显著降低脑血管事件发生的风险[1]。然而,随着抗血小板药物临床应用经验的积累,发现患者对该药物临床反应性存在显著的个体差异性。5%40%的患者对阿司匹林治疗无反应,4%30%的患者在服用氯吡格雷不能达到理想的抗血小板作用。而且,存在阿司匹林抵抗的患者常常合并氯吡格雷抵抗。因此,在处理急性
引用
收藏
页码:1002 / 1003
页数:2
相关论文
共 10 条
[1]  
Aspirin resistance: clinical significance and genetic polymorphism. Xu Z-H,Jiao J-R,Yang R,Luo B-Y,Wang X-F,Wu F. The Journal of international medical research . 2012
[2]  
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Mega Jessica L,Close Sandra L,Wiviott Stephen D,Shen Lei,Walker Joseph R,Simon Tabassome,Antman Elliott M,Braunwald Eugene,Sabatine Marc S. The Lancet . 2010
[3]  
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Sim Sarah C,Risinger Carl,Dahl Marja-Liisa,Aklillu Eleni,Christensen Magnus,Bertilsson Leif,Ingelman-Sundberg Magnus. Clinical Pharmacokinetics . 2006
[4]  
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heleen J. Bouman,Ankie M. Harmsze,Jochem W. van Werkum. Heart . 2011
[5]  
Aspirin plus clopidogrel in acute minor ischaemic stroke or transient ischaemic attack is superior to aspirin alone for stroke risk reduction:CHANCE trial. Gorelick PB,Farooq MU. Evid Based Med . 2014
[6]  
Paraoxonase-1 is a major determinant of clopidogrel efficacy. Heleen J Bouman,Edgar Sch?mig,Jochem W van Werkum,Janna Velder,Christian M Hackeng,Christoph Hirschh?user,Christopher Waldmann,Hans-Günther Schmalz,Jurri?n M ten Berg,Dirk Taubert. Nature Medicine . 2010
[7]  
Impact of P-glycoprotein on clopidogrel absorption. Dirk Taubert,Nicolas von Beckerath,Gundula Grimberg,Andreas Lazar,Norma Jung,Tobias Goeser,Adnan Kastrati,Albert Sch?mig,Edgar Sch?mig. Clinical Pharmacokinetics . 2006
[8]  
Cytochrome p-450 polymorphisms and response to clopidogrel. Mega Jessica L,Close Sandra L,Wiviott Stephen D,Shen Lei,Hockett Richard D,Brandt John T,Walker Joseph R,Antman Elliott M,Macias William,Braunwald Eugene,Sabatine Marc S. The New England Quarterly . 2008
[9]  
Cyclooxygenase Polymorphisms and Risk of Cardiovascular Events: The Atherosclerosis Risk in Communities (ARIC) Study. C R Lee,K E North,M S Bray,D J Couper,G Heiss,D C Zeldin. Clinical Pharmacokinetics . 2007
[10]  
The Cyclooxygenase-1 C50T Polymorphism Is Not Associated with Aspirin Responsiveness Status in Stable Coronary Artery Disease in Tunisian Patients. Tahar Chakroun,Faouzi Addad,Saloua Yacoub. GENETIC TESTING AND MOLECULAR BIOMARKERS . 2011